NAFLD (non-alcoholic fatt...

NAFLD (non-alcoholic fatty liver disease) is a term used to describe a condition where ≥5% of hepatocytes (liver cells) display macrovesicular steatosis (accumulation of fat) in individuals who drink little or no alcohol. It includes a spectrum of disease stages, ranging from NAFL (non-alcoholic fatty liver), which is characterized by hepatic steatosis and mild inflammation, to NASH (non-alcoholic steatohepatitis), which involves inflammation, cellular injury (ballooning), and fibrosis. The prevalence of NAFLD and NASH is increasing globally, largely due to the rising rates of obesity and metabolic comorbidities such as insulin resistance, dyslipidemia, central obesity, and hypertension. The estimated prevalence of NAFLD in adults is around 25% to 30% in the general population, but it often remains undiagnosed. The increasing prevalence of NAFLD and NASH underscores the importance of addressing obesity and metabolic comorbidities and implementing early detection and management strategies to prevent disease progression and reduce the burden of complications associated with these conditions. Vitamin E has been studied in the context of NASH treatment and has shown some benefits, particularly in improving certain histological features of the disease.